Effective delivery of anti-PD-L1 siRNA with human heavy chain ferritin (HFn) in acute myeloid leukemia cell lines.
Human heavy chain ferritin
Nanoparticle
PD-L1
siRNA
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
received:
20
03
2024
accepted:
24
04
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
13
5
2024
Statut:
epublish
Résumé
Because of the high biocompatibility, self-assembly capability, and CD71-mediated endocytosis, using human heavy chain ferritin (HFn) as a nanocarrier would greatly increase therapeutic effectiveness and reduce possible adverse events. Anti-PD-L1 siRNA can downregulate the level of PD-L1 on tumor cells, resulting in the activation of effector T cells against leukemia. Therefore, this study aimed to produce the tumor-targeting siPD-L1/HFn nanocarrier. Briefly, the HFn coding sequence was cloned into a pET-28a, and the constructed expression plasmid was subsequently transformed into E. coli BL21. After induction of Isopropyl β-D-1-thiogalactopyranoside (IPTG), HFn was purified with Ni-affinity chromatography and dialyzed against PBS. The protein characteristics were analyzed using SDS-PAGE, Western Blot, and Dynamic light scattering (DLS). The final concentration was assessed using the Bicinchoninic acid (BCA) assay. The encapsulation was performed using the standard pH system. The treatment effects of siPD-L1/HFn were carried out on HL-60 and K-562 cancer cell lines. The RT-PCR was used to determine the mRNA expression of PD-L1. The biocompatibility and excretion of siPD-L1/HFn have also been evaluated. The expression and purity of HFn were well verified through SDS-PAGE, WB, and DLS. RT-PCR analyses also showed significant siRNA-mediated PD-L1 silencing in both HL-60 and K-562 cells. Our study suggested a promising approach for siRNA delivery. This efficient delivery system can pave the way for the co-delivery of siRNAs and multiple chemotherapies to address the emerging needs of cancer combination therapy.
Identifiants
pubmed: 38739199
doi: 10.1007/s12032-024-02393-7
pii: 10.1007/s12032-024-02393-7
doi:
Substances chimiques
RNA, Small Interfering
0
B7-H1 Antigen
0
Apoferritins
9013-31-4
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
149Subventions
Organisme : Mazandran University of Medical Science
ID : 10600
Organisme : Mazandran University of Medical Science
ID : 10600
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Okazaki T, Honjo T. The PD-1–PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195–201.
doi: 10.1016/j.it.2006.02.001
pubmed: 16500147
de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;38(3):326–33.
doi: 10.1016/j.ccell.2020.07.004
pubmed: 32750319
Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19(1):60–71.
doi: 10.1016/j.chembiol.2011.12.008
pubmed: 22284355
pmcid: 3269031
Teo PY, et al. Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing. Adv Healthc Mater. 2015;4(8):1180–9.
doi: 10.1002/adhm.201500089
pubmed: 25866054
Hobo W, et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood. 2010;116(22):4501–11.
doi: 10.1182/blood-2010-04-278739
pubmed: 20682852
Tatiparti K, et al. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017;7(4):77.
doi: 10.3390/nano7040077
pubmed: 28379201
pmcid: 5408169
Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133–47.
doi: 10.1016/j.addr.2019.05.004
pubmed: 31102606
pmcid: 6745264
Tu Z, et al. Ferritin-based drug delivery system for tumor therapy. BMEMat. 2023;1:e12022.
doi: 10.1002/bmm2.12022
Pande A, et al. Expression of CD71 by flow cytometry in acute leukemias: more often seen in acute myeloid leukemia. Indian J Pathol Microbiol. 2016;59(3):310.
doi: 10.4103/0377-4929.188145
pubmed: 27510666
Khoshnejad M, et al. Ferritin-based drug delivery systems: hybrid nanocarriers for vascular immunotargeting. J Control Release. 2018;282:13–24.
doi: 10.1016/j.jconrel.2018.02.042
pubmed: 29522833
pmcid: 6008199
Yuan Z, et al. Rational design of engineered H-ferritin nanoparticles with improved siRNA delivery efficacy across an in vitro model of the mouse BBB. Nanoscale. 2022;14(17):6449–64.
doi: 10.1039/D1NR07880A
pubmed: 35416195
Wang Z, et al. Functional ferritin nanoparticles for biomedical applications. Front Chem Sci Eng. 2017;11:633–46.
doi: 10.1007/s11705-017-1620-8
pubmed: 29503759
pmcid: 5831262
Yang R, et al. Doxorubicin loaded ferritin nanoparticles for ferroptosis enhanced targeted killing of cancer cells. RSC Adv. 2019;9(49):28548–53.
doi: 10.1039/C9RA04478G
pubmed: 35529630
pmcid: 9071105
Bellini M, et al. Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in cancer cells. J Control Release. 2014;196:184–96.
doi: 10.1016/j.jconrel.2014.10.002
pubmed: 25312541
Wang F, et al. Iron and leukemia: new insights for future treatments. J Exp Clin Cancer Res. 2019;38:1–17.
doi: 10.1186/s13046-019-1397-3
Lebon D, et al. Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics. Leuk Res. 2015;39(8):818–21.
doi: 10.1016/j.leukres.2015.05.001
pubmed: 26002512
Benadiba J, et al. Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2017;58(6):1433–45.
doi: 10.1080/10428194.2016.1239257
pubmed: 27736268
Marsee DK, Pinkus GS, Yu H. CD71 (transferrin receptor) an effective marker for erythroid precursors in bone marrow biopsy specimens. Am J Clin Pathol. 2010;134(3):429–35.
doi: 10.1309/AJCPCRK3MOAOJ6AT
pubmed: 20716799
Liu Q, et al. Significance of CD71 expression by flow cytometry in diagnosis of acute leukemia. Leuk Lymphoma. 2014;55(4):892–8.
doi: 10.3109/10428194.2013.819100
pubmed: 23962073
Wei Y-Y, et al. Expression of CD71 on cell proliferation in hematologic malignancy and its correlation with Ki-67. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(1):234–40.
pubmed: 25687079
Zhao R, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Prolif. 2019;52(3):e12571.
doi: 10.1111/cpr.12571
pubmed: 30714229
pmcid: 6536456
Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.
doi: 10.1158/2159-8290.CD-18-0367
pubmed: 30115704
Yang H, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28(6):1280–8.
doi: 10.1038/leu.2013.355
pubmed: 24270737
Fan K, et al. Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat Nanotechnol. 2012;7(7):459–64.
doi: 10.1038/nnano.2012.90
pubmed: 22706697
van Ens D, et al. PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. Bone Marrow Transplant. 2020;55(12):2308–18.
doi: 10.1038/s41409-020-0966-6
pubmed: 32528120